Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias

Pharmacology and Therapeutics

Volumn 112, Issue 1, 2006, Pages 150-170

  Thomsen, Morten B ^a   Matz, Jørgen ^b   Volders, Paul G A ^c   Vos, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b H LUNDBECK A S   (Denmark)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Drug effects; Guidelines; IKr; QT prolongation; Repolarisation; Ventricular arrhythmias

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZIMILIDE; CISAPRIDE; CLOFILIUM; DOFETILIDE; DROPERIDOL; ERYTHROMYCIN; GREPAFLOXACIN; IBUTILIDE; LEVACETYLMETHADOL; METHOXAMINE; MOXIFLOXACIN; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; PRENYLAMINE; RANOLAZINE; SERTINDOLE; SOTALOL; TERFENADINE; TERODILINE; VERAPAMIL;

ACTION POTENTIAL; ALLERGIC RHINITIS; ANESTHESIA; ANGINA PECTORIS; ARRHYTHMOGENESIS; ARTERY PERFUSION; ATRIOVENTRICULAR BLOCK; BACTERIAL INFECTION; BIOLOGICAL MODEL; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; DISEASE MARKER; DISEASE PREDISPOSITION; DIZZINESS; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIZATION; ELECTROCARDIOGRAM; EXPERIMENTAL STUDY; GASTROINTESTINAL DISEASE; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART PALPITATION; HEART PERFUSION; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; IC 50; ION CURRENT; ISOLATED HEART; NONHUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATIENT CARE; POSTOPERATIVE NAUSEA; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; QT DISPERSION; QT INTERVAL; QT PROLONGATION; RABBIT; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH; T WAVE; TACHYCARDIA; TORSADE DES POINTES; URINE INCONTINENCE; WAVEFORM;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PHARMACEUTICAL PREPARATIONS; TORSADES DE POINTES;

EID: 33748086808     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.04.009     Document Type: Review

References (278)

1. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 (1999) 175-187
2. Abi-Gerges N., Small B.G., Lawrence C.L., Hammond T.G., Valentin J.P., and Pollard C.E. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 142 (2004) 1255-1264
3. Aiba T., Shimizu W., Inagaki M., Noda T., Miyoshi S., Ding W.G., et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 45 (2005) 300-307
4. Akar F.G., and Rosenbaum D.S. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 93 (2003) 638-645
5. Akar F.G., Yan G.X., Antzelevitch C., and Rosenbaum D.S. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 105 (2002) 1247-1253
6. Algra A., Tijssen J.G., Roelandt J.R., Pool J., and Lubsen J. Contribution of the 24 hour electrocardiogram to the prediction of sudden coronary death. Br Heart J 70 (1993) 421-427
7. Amos G.J., Abrahamsson C., Duker G., Hondeghem L., Palmer M., and Carlsson L. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential. Cardiovasc Res 49 (2001) 351-360
8. Anderson M.E. QT interval prolongation and arrhythmia: an unbreakable connection?. J Intern Med 259 (2006) 81-90
9. Anderson M.E., Mazur A., Yang T., and Roden D.M. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 296 (2001) 806-810
10. Angkeow P., Calkins H., Marban E., Tomaselli G.F., and Berger R.D. Ibutilide increases beat-to-beat repolarization lability in patients with heart disease. Circulation 104 (2001) 1818 (abstract)
11. 2+ release and repolarization lability in myocytes from the dog with chronic atrioventricular block (cAVB). Biophys J 88 (2005) 298A (abstract)
12. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?. J Electrocardiol 37 (2004) 15-24 (Suppl.)
13. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
14. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 17 (2002) 43-51
15. Antzelevitch C., Sun Z.Q., Zhang Z.Q., and Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 28 (1996) 1836-1848
16. Appleby L., Thomas S., Ferrier N., Lewis G., Shaw J., and Amos T. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 176 (2000) 405-406
17. Armoundas A.A., Rosenbaum D.S., Ruskin J.N., Garan H., and Cohen R.J. Prognostic significance of electrical alternans versus signal averaged electrocardiography in predicting the outcome of electrophysiological testing and arrhythmia-free survival. Heart 80 (1998) 251-256
18. Armoundas A.A., Nanke T., and Cohen R.J. Images in cardiovascular medicine. T-wave alternans preceding torsade de pointes ventricular tachycardia. Circulation 101 (2000) 2550
19. Armoundas A.A., Tomaselli G.F., and Esperer H.D. pathophysiological basis and clinical application of T-wave alternans. J Am Coll Cardiol 40 (2002) 207-217
20. Atiga W.L., Calkins H., Lawrence J.H., Tomaselli G.F., Smith J.M., and Berger R.D. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 9 (1998) 899-908
21. Atiga W.L., Fananapazir L., McAreavey D., Calkins H., and Berger R.D. Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation 101 (2000) 1237-1242
22. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 45 (2000) 557-559
23. Bass A.S., Tomaselli G., Bullingham III R., and Kinter L.B. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 52 (2005) 12-21
24. Batchvarov V.N., Ghuran A., Smetana P., Hnatkova K., Harries M., Dilaveris P., et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282 (2002) H2356-H2363
25. Batey A.J., and Coker S.J. Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol 135 (2002) 1003-1012
26. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24 (2003) 619-625
27. Berger R.D., Kasper E.K., Baughman K.L., Marban E., Calkins H., and Tomaselli G.F. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 96 (1997) 1557-1565
28. Bigger Jr. J.T. The predictive value of RR variability and baroreflex sensitivity in coronary heart disease. Card Electrophysiol Rev 1 (1997) 198-204
29. Bilchick K., Viitasalo M., Oikarinen L., Fetics B., Tomaselli G., Swan H., et al. Temporal repolarization lability differences among genotyped patients with the long QT syndrome. Am J Cardiol 94 (2004) 1312-1316
30. Billman, G. E. (in press). A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. Pharmacol Ther (E-publication ahead of print, doi:10.1016/j.pharmthera.2006.01.002).
31. Bischoff U., Schmidt C., Netzer R., and Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 406 (2000) 341-343
32. Bjorkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J Pharmacokinet Pharmacodyn 30 (2003) 285-307
33. Brendorp B., Pedersen O., Torp-Pedersen C., Sahebzadah N., and Kober L. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 25 (2002) 847-865
34. Brennan M., Palaniswami M., and Kamen P. Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability?. IEEE Trans Biomed Eng 48 (2001) 1342-1347
35. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linee P., et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276 (1996) 637-646
36. Brooks R.R., Drexler A.P., Maynard A.E., Al-Khalidi H., and Kostreva D.R. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. Proc Soc Exp Biol Med 223 (2000) 183-189
37. Brugada R., Hong K., Dumaine R., Cordeiro J., Gaita F., Borggrefe M., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109 (2004) 30-35
38. Buchanan L.V., Kabell G., Brunden M.N., and Gibson J.K. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 22 (1993) 540-549
39. Burashnikov A., and Antzelevitch C. Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol 13 (2002) 172-177
40. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 259 (2006) 70-80
41. Carlsson L., Almgren O., and Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 16 (1990) 276-285
42. Carlsson L., Abrahamsson C., Andersson B., Duker G., and Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 27 (1993) 2186-2193
43. Carlsson L., Drews L., and Duker G. Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload. J Pharmacol Exp Ther 279 (1996) 231-239
44. Carlsson L., Amos G.J., Andersson B., Drews L., Duker G., and Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?. J Pharmacol Exp Ther 282 (1997) 220-227
45. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262 (1992) 809-817
46. + currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 124 (1998) 663-668
47. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 79 (1999) 917-1017
48. Chauhan V.S., Krahn A.D., Walker B.D., Klein G.J., Skanes A.C., and Yee R. Sex differences in QTc interval and QT dispersion: dynamics during exercise and recovery in healthy subjects. Am Heart J 144 (2002) 858-864
49. Chen X., Cass J.D., Bradley J.A., Dahm C.M., Sun Z., Kadyszewski E., et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 146 (2005) 792-799
50. Chen Y.J., Hsieh M.H., Chiou C.W., and Chen S.A. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol 34 (1999) 237-247
51. Chiang C.E., Wang T.M., and Luk H.N. Inhibition of L-type Ca(2+) current in Guinea pig ventricular myocytes by cisapride. J Biomed Sci 11 (2004) 303-314
52. Chiba K., Sugiyama A., Satoh Y., Shiina H., and Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 169 (2000) 8-16
53. Chiba K., Sugiyama A., Hagiwara T., Takahashi S., Takasuna K., and Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol 486 (2004) 189-200
54. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54 (1998) 695-703
55. Choy A.M., Lang C.C., Chomsky D.M., Rayos G.H., Wilson J.R., and Roden D.M. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 96 (1997) 2149-2154
56. Claycomb W.C., Lanson Jr. N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95 (1998) 2979-2984
57. Connolly S.J., Schnell D.J., Page R.L., Wilkinson W.E., Marcello S.R., and Pritchett E.L. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 88 (2001) 974-979
58. Crumb Jr. W.J. Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292 (2000) 261-264
59. D'Alonzo A.J., Zhu J.L., and Darbenzio R.B. Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe. Eur J Pharmacol 369 (1999) 57-64
60. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 3 (2001) K70-K80
61. De Bruin M.L., van Puijenbroek E.P., Egberts A.C., Hoes A.W., and Leufkens H.G. Non-sedating antihistamine drugs and cardiac arrhythmias- biased risk estimates from spontaneous reporting systems?. Br J Clin Pharmacol 53 (2002) 370-374
62. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., and Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 25 (2002) 263-286
63. Derakhchan K., Cardinal R., Brunet S., Klug D., Pharand C., Kus T., et al. Polymorphic ventricular tachycardias induced by d-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry. Cardiovasc Res 38 (1998) 617-630
64. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 59 (1966) 263-272
65. Detre E., Thomsen M.B., Beekman J.D., Petersen K.U., and Vos M.A. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. Br J Pharmacol 145 (2005) 397-404
66. Di Diego J.M., Belardinelli L., and Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108 (2003) 1027-1033
67. Di Diego J.M., Cordeiro J.M., Goodrow R.J., Fish J.M., Zygmunt A.C., Perez G.J., et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 106 (2002) 2004-2011
68. Drici M.D. Influence of gender on drug-acquired long QT syndrome. Eur Heart J Suppl 3 (2001) K41-K47
69. Drici M.D., Burklow T.R., Haridasse V., Glazer R.I., and Woosley R.L. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 94 (1996) 1471-1474
70. Drici M.D., and Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24 (2001) 575-585
71. Drolet B., Khalifa M., Daleau P., Hamelin B.A., and Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97 (1998) 204-210
72. Eckardt L., Haverkamp W., Mertens H., Johna R., Clague J.R., Borggrefe M., et al. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin. J Cardiovasc Pharmacol 32 (1998) 425-434
73. Eckardt L., Breithardt G., and Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300 (2002) 64-71
74. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., and Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 301 (2002) 427-434
75. El-Sherif N., and Turitto G. The long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol 22 (1999) 91-110
76. EMEA. (1997). The European Agency for the Evaluation of Medicinal Products. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. In: CPMP/986/96.
77. Emori T., and Antzelevitch C. Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol 12 (2001) 1369-1378
78. Etminan M., Carleton B., and Rochon P.A. Quantifying adverse drug events: are systematic reviews the answer?. Drug Saf 27 (2004) 757-761
79. Extramiana F., and Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 110 (2004) 3661-3666
80. Extramiana F., Maison-Blanche P., Badilini F., Beaufils P., and Leenhardt A. Individual QT-R-R relationship: average stability over time does not rule out an individual residual variability: implication for the assessment of drug effect on the QT interval. Ann Noninvasive Electrocardiol 10 (2005) 169-178
81. Farkas A., and Coker S.J. Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. Eur J Pharmacol 449 (2002) 143-153
82. Farkas A., Lepran I., and Papp J.G. Proarrhythmic effects of intravenous quinidine, amiodarone, d-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol 39 (2002) 287-297
83. Fenichel R.R., Malik M., Antzelevitch C., Sanguinetti M.C., Roden D.M., Priori S.G., et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15 (2004) 475-495
84. Fermini B., Jurkiewicz N.K., Jow B., Guinosso Jr. P.J., Baskin E.P., Lynch Jr. J.J., et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26 (1995) 259-271
85. Ficker E., Kuryshev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66 (2004) 33-44
86. Fish J.M., Di Diego J.M., Belardinelli L., and Antzelevitch C. Moxifloxacin-induced torsade de pointes in an experimental model of long QT syndrome. Heart Rhythm 2 (2005) S108 (abstract)
87. Fish J.M., Di Diego J.M., Nesterenko V., and Antzelevitch C. Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization. Implications for biventricular pacing. Circulation 109 (2004) 2135-2141
88. Fossa A.A., Wisialowski T., Wolfgang E., Wang E., Avery M., Raunig D.L., et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol 486 (2004) 209-221
89. Fung M.C., Hsiao-hui Wu J., and Kwong K. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades. Pharmacoepidemiol Drug Saf 9 (2000) S24-S25 (abstract)
90. Gaita F., Giustetto C., Bianchi F., Wolpert C., Schimpf R., Riccardi R., et al. Short QT Syndrome: a familial cause of sudden death. Circulation 108 (2003) 965-970
91. Gbadebo T.D., Trimble R.W., Khoo M.S., Temple J., Roden D.M., and Anderson M.E. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 105 (2002) 770-774
92. Geddes L.A. Electrocardiograms from the turtle to the elephant that illustrate interesting physiological phenomena. Pacing Clin Electrophysiol 25 (2002) 1762-1770
93. Gilmour Jr. R.F., Riccio M.L., Locati E.H., Maison-Blanche P., Coumel P., and Schwartz P.J. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with aquired QT prolongation. J Am Coll Cardiol 30 (1997) 209-217
94. Gintant G.A. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes. J Cardiovasc Pharmacol 31 (1998) 945-953
95. Gintant G.A., Limberis J.T., McDermott J.S., Wegner C.D., and Cox B.F. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37 (2001) 607-618
96. Goldhaber J.I., Xie L.H., Duong T., Motter C., Khuu K., and Weiss J.N. Action potential duration restitution and alternans in rabbit ventricular myocytes: the key role of intracellular calcium cycling. Circ Res 96 (2005) 459-466
97. Gussak I., Brugada P., Brugada J., Wright R.S., Kopecky S.L., Chaitman B.R., et al. Idiopathic short QT interval: a new clinical syndrome?. Cardiology 94 (2000) 99-102
98. Haigney M.C., Zareba W., Gentlesk P.J., Goldstein R.E., Illovsky M., McNitt S., et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 44 (2004) 1481-1487
99. Hammond T.G., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Redfern W.S., et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 49 (2001) 741-750
100. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47 (2000) 219-233
101. Haverkamp W., Martinez-Rubio A., Hief C., Lammers A., Muhlenkamp S., Wichter T., et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 30 (1997) 487-495
102. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., and Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342 (1993) 1007-1011
103. Hohnloser S.H. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 80 (1997) 82G-89G
104. Hohnloser S.H., Klingenheben T., and Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121 (1994) 529-535
105. Hohnloser S.H., Klingenheben T., Li Y.G., Zabel M., Peetermans J., and Cohen R.J. T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers. J Cardiovasc Electrophysiol 9 (1998) 1258-1268
106. Hohnloser S.H., Klingenheben T., Bloomfield D., Dabbous O., and Cohen R.J. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol 41 (2003) 2220-2224
107. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 41 (2003) 14-24
108. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
109. Hondeghem L.M., Dujardin K., and DeClerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res 50 (2001) 345-353
110. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 14 (2003) 287-294
111. ICH-E14. (2005). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). www.ich.org
112. ICH-S7B. (2005). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). www.ich.org
113. Ikeda T., Saito H., Tanno K., Shimizu H., Watanabe J., Ohnishi Y., et al. T-wave alternans as a predictor for sudden cardiac death after myocardial infarction. Am J Cardiol 89 (2002) 79-82
114. Janse M.J., Sosunov E.A., Coronel R., Opthof T., Anyukhovsky E.P., de Bakker J.M., et al. Repolarization gradients in the canine left ventricle before and after induction of short-term cardiac memory. Circulation 112 (2005) 1711-1718
115. Johansson M., and Carlsson L. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome. J Cardiovasc Pharmacol Ther 6 (2001) 247-254
116. Josephson M., and Wellens H.J. Implantable defibrillators and sudden cardiac death. Circulation 109 (2004) 2685-2691
117. Ks in human ventricular muscle. Circulation 112 (2005) 1392-1399
118. + current by dofetilide. Circ Res 72 (1993) 75-83
119. Kamiya K., Nishiyama A., Yasui K., Hojo M., Sanguinetti M.C., and Kodama I. Short-and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 103 (2001) 1317-1324
120. + channel HERG. Mol Pharmacol 59 (2001) 122-126
121. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., and Ebert S.N. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316 (2006) 1098-1106
122. Kaufman E.S., Priori S.G., Napolitano C., Schwartz P.J., Iyengar S., Elston R.C., et al. Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. J Cardiovasc Electrophysiol 12 (2001) 455-461
123. Kiehn J., Thomas D., Karle C.A., Schols W., and Kubler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 212-219
124. Kii Y., and Ito T. Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. Pharmacol Toxicol 90 (2002) 246-253
125. Kirchhof P., Degen H., Franz M.R., Eckardt L., Fabritz L., Milberg P., et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J Pharmacol Exp Ther 305 (2003) 257-263
126. Kligfield P., Lax K.G., and Okin P.M. QT interval-heart rate relation during exercise in normal men and women: definition by linear regression analysis. J Am Coll Cardiol 28 (1996) 1547-1555
127. Klingenheben T., Zabel M., D'Agostino R.B., Cohen R.J., and Hohnloser S.H. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet 356 (2000) 651-652
128. + channel family by ebastine. J Pharmacol Exp Ther 281 (1997) 233-244
129. Kodama I., Kamiya K., and Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 35 (1997) 13-29
130. Kozhevnikov D.O., Yamamoto K., Robotis D., Restivo M., and El-Sherif N. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation 105 (2002) 1128-1134
131. Kroll C.R., and Gettes L.S. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol 13 (2002) 936-938
132. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312 (2005) 316-323
133. Lacerda A.E., Kramer J., Shen K.-Z., Thomas D., and Brown A.M. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Suppl 3 (2001) K23-K30
134. Lacroix P., Crumb W.J., Durando L., and Ciottoli G.B. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 477 (2003) 69-72
135. Lawrence D.M., Holman C.D., Jablensky A.V., and Hobbs M.S. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 182 (2003) 31-36
136. Leichter D., Danilo Jr. P., Boyden P., Rosen T.S., and Rosen M.R. A canine model of torsades de pointes. Pacing Clin Electrophysiol 11 (1988) 2235-2245
137. Leishman D.J., Helliwell R., Wakerell J., and Wallis R.M. Effects of E-4031, cisapride, terfenadine and terodiline on cardiac repolarisation in canine Purkinje fibre and HERG channels expressed in HEK293 cells. Br J Pharmacol 133 (2001) 130P (abstract)
138. Lengyel C., Iost N., Virag L., Varro A., Lathrop D.A., and Papp J.G. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br J Pharmacol 132 (2001) 101-110
139. + current in human ventricular myocytes. Circ Res 78 (1996) 689-696
140. Lipsky B.A., and Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28 (1999) 352-364
141. Ks contributes to the longer action potential of the M cell. Circ Res 76 (1995) 351-365
142. Liu D.W., Gintant G.A., and Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res 72 (1993) 671-687
143. Liu T., Choi B.R., Drici M.D., and Salama G. Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with Long QT 2. J Cardiovasc Electrophysiol 16 (2005) 516-524
144. Lu H.R., Marien R., Saels A., and DeClerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 12 (2001) 93-102
145. Lu H.R., Remeysen P., and De Clerck F. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol 36 (2000) 728-736
146. Lu H.R., Remeysen P., Somers K., Saels A., and De Clerck F. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 12 (2001) 538-545
147. Lu Y., and Wang Z. Terfenadine block of sodium current in canine atrial myocytes. J Cardiovasc Pharmacol 33 (1999) 507-513
148. Lupoglazoff J.M., Denjoy I., Berthet M., Neyroud N., Demay L., Richard P., et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations. Circulation 103 (2001) 1095-1101
149. Lynch Jr. J.J., Houle M.S., Stump G.L., Wallace A.A., Gilberto D.B., Jahansouz H., et al. Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia. Circulation 100 (1999) 917-922
150. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., and Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
151. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12 (2001) 411-420
152. Malik M., and Bradford A. Human precision of operating a digitizing board: implications for electrocardiogram measurements. Pacing Clin Electrophysiol 21 (1998) 1656-1662
153. Malik M., Hnatkova K., and Batchvarov V. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTC prolongation. Pacing Clin Electrophysiol 27 (2004) 791-800
154. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43 (2004) 369-379
155. Martin R.M., Kapoor K.V., Wilton L.V., and Mann R.D. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 317 (1998) 119-120
156. Mattioni T.A., Zheutlin T.A., Sarmiento J.J., Parker M., Lesch M., and Kehoe R.F. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med 111 (1989) 574-580
157. Mazur A., Roden D.M., and Anderson M.E. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation 100 (1999) 2437-2442
158. Merot J., Probst V., Debailleul M., Gerlach U., Moise N.S., LeMarec H., et al. Electropharmacological characterization of cardiac repolarization in German shepherd dogs with an inherited syndrome of sudden death: abnormal response to potassium channel blockers. J Am Coll Cardiol 36 (2000) 939-947
159. Milberg P., Eckardt L., Bruns H.J., Biertz J., Ramtin S., Reinsch N., et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar qt prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303 (2002) 218-225
160. Milberg P., Haverkamp W., Monnig G., Talebpour F., Breithardt G., and Eckardt L. Quinolones and proarrhythmia: differgent torsadogenic potential despite similar effects in myocardial repolarization. Heart Rhythm 2 (2005) S137 (abstract)
161. Milberg P., Ramtin S., Monnig G., Osada N., Wasmer K., Breithardt G., et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol 44 (2004) 278-286
162. Milberg P., Reinsch N., Wasmer K., Monnig G., Stypmann J., Osada N., et al. Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 65 (2005) 397-404
163. + channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 26 (1995) 761-769
164. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273 (1997) H2534-H2538
165. Moise N.S., Meyers-Wallen V., Flahive W.J., Valentine B.A., Scarlett J.M., Brown C.A., et al. Inherited ventricular arrhythmias and sudden death in German shepherd dogs. J Am Coll Cardiol 24 (1994) 233-243
166. Moore N., Hall G., Sturkenboom M., Mann R., Lagnaoui R., and Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12 (2003) 271-281
167. Murabayashi T., Fetics B., Kass D., Nevo E., Gramatikov B., and Berger R.D. Beat-to-beat QT interval variability associated with acute myocardial ischemia. J Electrocardiol 35 (2002) 19-25
168. Nguyen P.T., Scheinman M.M., and Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 74 (1986) 340-349
169. Pajouh M., Wilson L.D., Poelzing S., Johnson N.J., and Rosenbaum D.S. I(Ks) blockade reduces dispersion of repolarization in heart failure. Heart Rhythm 2 (2005) 731-738
170. Pak P.H., Nuss H.B., Tunin R.S., Kaab S., Tomaselli G.F., Marban E., et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 30 (1997) 576-584
171. Petersen C.I., McFarland T.R., Stepanovic S.Z., Yang P., Reiner D.J., Hayashi K., et al. In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A 101 (2004) 11773-11778
172. Pham T.V., Sosunov E.A., Gainullin R.Z., Danilo Jr. P., and Rosen M.R. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 103 (2001) 2207-2212
173. Potet F., Bouyssou T., Escande D., and Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 299 (2001) 1007-1012
174. Pratt C.M., Camm A.J., Cooper W., Friedman P.L., MacNeil D.J., Moulton K.M., et al. Mortality in the Survival With ORal d-sotalol (SWORD) trial: why did patients die?. Am J Cardiol 81 (1998) 869-876
175. Pruvot E.J., Katra R.P., Rosenbaum D.S., and Laurita K.R. Role of calcium cycling versus restitution in the mechanism of repolarization alternans. Circ Res 94 (2004) 1083-1090
176. Raghunandan D.S., Desai N., Mallavarapu M., Berger R.D., and Yeragani V.K. Increased beat-to-beat QT variability in patients with congestive cardiac failure. Indian Heart J 57 (2005) 138-142
177. Rampe D., Roy M.L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417 (1997) 28-32
178. Rampe D., Murawsky M.K., Grau J., and Lewis E.W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286 (1998) 788-793
179. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 (2003) 32-45
180. Restivo M., Caref E.B., Kozhevnikov D.O., and El-Sherif N. Spatial dispersion of repolarization is a key factor in the arrhythmogenicity of long QT syndrome. J Cardiovasc Electrophysiol 15 (2004) 323-331
181. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21 (1998) 1029-1034
182. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
183. Roden D.M., Balser J.R., George Jr. A.L., and Anderson M.E. Cardiac ion channels. Annu Rev Physiol 64 (2002) 431-475
184. Rosenbaum D.S., Jackson L.E., Smith J.M., Garan H., Ruskin J.N., and Cohen R.J. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 330 (1994) 235-241
185. Roy M., Dumaine R., and Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94 (1996) 817-823
186. Salata J.J., Jurkiewicz N.K., Wallace A.A., Stupienski III R.F., Guinosso Jr. P.J., and Lynch Jr. J.J. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76 (1995) 110-119
187. Kr potassium channel. Cell 81 (1995) 299-307
188. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96 (1990) 195-215
189. Sarzi Braga S., Vaninetti R., Laporta A., Picozzi A., and Pedretti R.F.E. T wave alternans is a predictor of death in patients with congestive heart failure. Int J Cardiol 93 (2004) 31-38
190. Schneider J., Hauser R., Andreas J.O., Linz K., and Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol 512 (2005) 53-60
191. Schoenmakers M., Ramakers C., van Opstal J.M., Leunissen J.D., Londono C., and Vos M.A. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 59 (2003) 351-359
192. Schram G., Zhang L., Derakhchan K., Ehrlich J.R., Belardinelli L., and Nattel S. Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 142 (2004) 1300-1308
193. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 (2001) 89-95
194. Senges J.C., Sterns L.D., Freigang K.D., Bauer A., Becker R., Kubler W., et al. Cesium chloride induced ventricular arrhythmias in dogs: three-dimensional activation patterns and their relation to the cesium dose applied. Basic Res Cardiol 95 (2000) 152-162
195. Shah R.R. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 36 Suppl. 1 (2004) 47-52
196. Shah R.R. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 27 (2004) 145-172
197. Shah R.R. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?. J Electrocardiol 38 (2005) 10-18
198. Shah R.R. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 28 (2005) 1009-1028
199. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
200. Shimizu W., and Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96 (1997) 2038-2047
201. Shimizu W., and Antzelevitch C. Cellular and ionic basis for T-wave alternans under long-QT conditions. Circulation 99 (1999) 1499-1507
202. Shimizu W., and Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 102 (2000) 706-712
203. Shimizu W., McMahon B., and Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 10 (1999) 154-164
204. Sicouri S., Fish J., and Antzelevitch C. Distribution of M cells in the canine ventricle. J Cardiovasc Electrophysiol 5 (1994) 824-837
205. Sipido K.R., Volders P.G., de Groot S.H., Verdonck F., Van de Werf F., Wellens H.J., et al. Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 102 (2000) 2137-2144
206. Smith J.M., Clancy E.A., Valeri C.R., Ruskin J.N., and Cohen R.J. Electrical alternans and cardiac electrical instability. Circulation 77 (1988) 110-121
207. Snyders D.J., and Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 49 (1996) 949-955
208. Sredniawa B., Musialik-Lydka A., Jarski P., Kalarus Z., and Polonski L. Circadian and sex-dependent QT dynamics. Pacing Clin Electrophysiol 28 Suppl. 1 (2005) S211-S216
209. Stahlmann R., and Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 40 Suppl. A (1997) 83-92
210. Stambler B.S., Wood M.A., Ellenbogen K.A., Perry K.T., Wakefield L.K., and VanderLugt J.T. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94 (1996) 1613-1621
211. Stass H., Dalhoff A., Kubitza D., and Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42 (1998) 2060-2065
212. Ks downregulation in canine ventricular hypertrophy confers the loss of ß-adrenergic-induced shortening of repolarization, favoring proarrhythmia. Circulation 110 (2005) 319-320 (abstract)
213. Stramba-Badiale M., Locati E.H., Martinelli A., Courville J., and Schwartz P.J. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 18 (1997) 1000-1006
214. Sugiyama A., Ishida Y., Satoh Y., Aoki S., Hori M., Akie Y., et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol 88 (2002) 341-350
215. Sugiyama A., Satoh Y., Shiina H., Takeda S., and Hashimoto K. Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J Cardiovasc Pharmacol 40 (2002) 235-245
216. Sugiyama A., Satoh Y., Takahara A., Nakamura Y., Shimizu-Sasamata M., Sato S., et al. Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol 466 (2003) 137-146
217. +channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 54 (1998) 113-121
218. Takacs J., Iost N., Lengyel C., Virag L., Nesic M., Varro A., et al. Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations. Eur J Pharmacol 470 (2003) 163-170
219. Takahara A., Sugiyama A., Ishida Y., Satoh Y., Wang K., Nakamura Y., et al. Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol 147 (2006) 634-641
220. Thomsen M.B., Volders P.G., Stengl M., Spätjens R.L., Beekman J.D., Bischoff U., et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 307 (2003) 776-784
221. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., Van Opstal J.M., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453-2459
222. Thomsen M.B., Truin M., vanOpstal J.M., Beekman J.D., Volders P.G., Stengl M., et al. Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 100 (2005) 279-287
223. Thomsen M.B., Volders P.G., Beekman J.D., Matz J., and Vos M.A. Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. Heart Rhythm 2 (2005) S104 (abstract)
224. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 199 (2004) 52-60
225. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., Kober L., Sandoe E., Egstrup K., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341 (1999) 857-865
226. Tseng G.N. I(Kr): the hERG channel. J Mol Cell Cardiol 33 (2001) 835-849
227. Tsuboi M., and Antzelevitch C. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm 3 (2006) 328-335
228. Tsuji Y., Zicha S., Qi X.Y., Kodama I., and Nattel S. Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. Circulation 113 (2006) 345-355
229. van der Linde H., Van de Water A., Loots W., Van Deuren B., Lu H.R., Van Ammel K., et al. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs. J Pharmacol Toxicol Methods 52 (2005) 168-177
230. van der Zande J., Vos M.A., Fazekas T., and Wellens H.J. The dose-dependent increase in interventricular dispersion of repolarization after ibutilide causes the transition from repetitive ectopic beats to torsade de pointes arrhythmias. Eur Heart J 17 (1996) 596 (abstract)
231. van Opstal J.M., Leunissen J.D., Wellens H.J., and Vos M.A. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of torsade de pointes arrhythmias. Eur J Pharmacol 412 (2001) 67-76
232. van Opstal J.M., Schoenmakers M., Verduyn S.C., de Groot S.H., Leunissen J.D., Der Hulst F.F., et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104 (2001) 2722-2727
233. van Opstal J.M., Verduyn S.C., Winckels S.K., Leerssen H.M., Leunissen J.D., Wellens H.J., et al. The JT-area indicates dispersion of repolarization in dogs with atrioventricular block. J Interv Card Electrophysiol 6 (2002) 113-120
234. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 26 (1995) 847-854
235. Ks in dog ventricular muscle and Purkinje fibre repolarization. J Physiol 523 (2000) 67-81
236. Varro A., Virag L., and Papp J.G. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol 117 (1996) 1181-1186
237. Verduyn S.C., Ramakers C., Snoep G., Leunissen J.D., Wellens H.J., and Vos M.A. Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling. Am J Physiol Heart Circ Physiol 280 (2001) H2882-H2890
238. Verduyn S.C., van Opstal J.M., Leunissen J.D., and Vos M.A. Assessment of the pro-arrhythmic potential of anti-arrhythmic drugs: an experimental approach. J Cardiovasc Pharmacol Ther 6 (2001) 89-97
239. Verduyn S.C., Vos M.A., van der Zande J., Kulcsar A., and Wellens H.J. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol 30 (1997) 1575-1584
240. Verduyn S.C., Vos M.A., van der Zande J., van der Hulst F.F., and Wellens H.J. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res 34 (1997) 453-463
241. Viskin S., Rosovski U., Sands A.J., Chen E., Kistler P.M., Kalman J.M., et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2 (2005) 569-574
242. Ks are larger in right than left canine ventricular midmyocardium. Circulation 99 (1999) 206-210
243. Volders P.G., Sipido K.R., Vos M.A., Kulcsar A., Verduyn S.C., and Wellens H.J. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 98 (1998) 1136-1147
244. Volders P.G., Sipido K.R., Vos M.A., Spatjens R.L., Leunissen J.D., Carmeliet E., et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 100 (1999) 2455-2461
245. Volders P.G., Vos M.A., Szabo B., Sipido K.R., de Groot S.H., Gorgels A.P., et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46 (2000) 376-392
246. Vos M.A., Verduyn S.C., Gorgels A.P., Lipcsei G.C., and Wellens H.J. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 91 (1995) 864-872
247. Vos M.A., deGroot S.H., Verduyn S.C., van der Zande J., Leunissen H.D., Cleutjens J.P., et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98 (1998) 1125-1135
248. Vos M.A., Gorenek B., Verduyn S.C., van der Hulst F.F., Leunissen J.D., Dohmen L., et al. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc Res 48 (2000) 421-429
249. + channels expressed in Xenopus oocytes. Cell Physiol Biochem 9 (1999) 81-89
250. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-sotalol. Lancet 348 (1996) 7-12
251. Walker M.L., and Rosenbaum D.S. Repolarization alternans: implications for the mechanism and prevention of sudden cardiac death. Cardiovasc Res 57 (2003) 599-614
252. Walker B.D., Singleton C.B., Bursill J.A., Wyse K.R., Valenzuela S.M., Qiu M.R., et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 128 (1999) 444-450
253. Walker B.D., Singleton C.B., Tie H., Bursill J.A., Wyse K.R., Valenzuela S.M., et al. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc Res 48 (2000) 44-58
254. Walker M.L., Wan X., Kirsch G.E., and Rosenbaum D.S. Hysteresis effect implicates calcium cycling as a mechanism of repolarization alternans. Circulation 108 (2003) 2704-2709
255. Wan X., Laurita K.R., Pruvot E.J., and Rosenbaum D.S. Molecular correlates of repolarization alternans in cardiac myocytes. J Mol Cell Cardiol 39 (2005) 419-428
256. Wang J., Della Penna K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., et al. Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284 (2003) H256-H267
257. Weerapura M., Nattel S., Chartier D., Caballero R., and Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. J Physiol 540 (2002) 15-27
258. Weissenburger J., Davy J.M., Chezalviel F., Ertzbischoff O., Poirier J.M., Engel F., et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther 259 (1991) 871-883
259. Wiseman L.R., and Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 47 (1994) 116-152
260. Woosley R.L., Chen Y., Freiman J.P., and Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269 (1993) 1532-1536
261. Wu L., Shryock J.C., Song Y., and Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 316 (2006) 718-726
262. Wu Y., Carlsson L., Liu T., Kowey P.R., and Yan G.X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 16 (2005) 898-904
263. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
264. Yan G.X., Shimizu W., and Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 98 (1998) 1921-1927
265. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 (2001) 2851-2856
266. Kr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 91 (1995) 1799-1806
267. Kr block and torsades de pointes. Circulation 96 (1997) I-554
268. Yang T., Snyders D., and Roden D.M. Drug block of I(Kr) model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38 (2001) 737-744
269. Yao J.A., and Tseng G.N. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 8 (1997) 184-198
270. Yoshida H., Sugiyama A., Satoh Y., Ishida Y., Yoneyama M., Kugiyama K., et al. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J 66 (2002) 758-762
271. Zabel M., Hohnloser S.H., Behrens S., Li Y.G., Woosley R.L., and Franz M.R. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol 8 (1997) 1148-1158
272. Zabel M., Hohnloser S.H., Behrens S., Woosley R.L., and Franz M.R. Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 8 (1997) 1239-1245
273. + current in ventricular myocytes of the guinea pig type. Theoretical formulation and their role in repolarization. Circ Res 77 (1995) 140-152
274. Zhang S., Sawanobori T., Hirano Y., and Hiraoka M. Multiple modulations of action potential duration by different calcium channel blocking agents in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 30 (1997) 489-496
275. Zhang S., Zhou Z., Gong Q., Makielski J.C., and January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84 (1999) 989-998
276. Zhou Z., Vorperian V.R., Gong Q., Zhang S., and January C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10 (1999) 836-843
277. Zitron E., Scholz E., Owen R.W., Luck S., Kiesecker C., Thomas D., et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 111 (2005) 835-838
278. Zygmunt A.C., Eddlestone G.T., Thomas G.P., Nesterenko V.V., and Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 281 (2001) H689-H697